we care
«The Company of Decade - the Russian pharmaceutical products manufacturer»

Over The Counter (OTC)

In 2011, the Company's revenue from sales of OTC products amounted to RUR 15,438.6 million; the deviation from the figures for 2010 was to RUR -142.5 million or -0.9%.



2011

2010

Volume 11/10

Sales 11/10

BRAND

Volume (mln packs)

Sales (mln RUR)

% of total sales

Volume (mln packs)

Sales (mln RUR)

% of total sales

Change

%

Change

%

1

Arbidol

25.839

4011

26.0%

42.640

5589

35.9%

-16.802

-39.4%

-1,579

-28.2%

2

Pentalgin

41.915

2375

15.4%

38.124

1988

12.8%

3.791

9.9%

387

19.4%

3

Complivit

16.608

1458

9.4%

14.903

1228

7.9%

1.705

11.4%

230

18.7%

4

Terpincod

7.782

1207

7.8%

7.470

1047

6.7%

0.312

4.2%

160

15.3%

5

Codelac

9.858

872

5.7%

8.317

692

4.4%

1.542

18.5%

181

26.1%

6

Afobazol

4.991

772

5.0%

4.093

607

3.9%

0.898

21.9%

165

27.1%

7

Flucustat

5.724

709

4.6%

5.609

653

4.2%

0.116

2.1%

56

8.5%

8

Amixin

1.162

528

3.4%

1.208

514

3.3%

-0.045

-3.8%

14

2.7%

9

Acypol

2.157

283

1.8%

1.164

141

0.9%

0.993

85.3%

143

101.5%

10

Corvalol

42.444

267

1.7%

41.986

230

1.5%

0.458

1.1%

37

16.2%

TOP 10 total

158.480

12,483

80.9%

165.514

12,690

81.4%

-7.034

-4.2%

-207

-1.6%

Other brands

453.270

2,956

19.1%

498.566

2,892

18.6%

-45.296

-9.1%

65

2.2%

TOTAL SALES

611.750

15,439

100.0%

664.080

15,581

100.0%

-52.330

-7.9%

-142

-0.9%


* only Flucostat tablets


** only Amixin №125

Sales of Arbidol® in 2011 amounted to RUR 4,011 million, a reduction of 28.2% or RUR 1,579 million vs. RUR 5,589 million a year earlier.

This change in sales of this product is caused by the reduction in orders, which manufacturers of pharmaceutical products receive from distributors, due to the stable epidemiological situation in Russia, according to Rospotrebnadzor (Federal Service on Customers' Rights, Protections and Human Well-Being Surveillance), and also due to the stockpiles of such products in distributors' warehouses sufficient for maintenance of the current level of consumption.

Except this deviation in Arbidol® sales figures, other OTC Pharmstandard products enjoyed steady growth both and volume and in value terms.

A simulation of OTC portfolio sales excluding Arbidol® shows that the Company's revenue from OTC products in 2011 would have amounted to RUR 11,427.8 million representing an increase of 14.4.% or RUR 1,436.1 million vs. the same period the previous year.

Products






Menu
Company profile Mission Strategy Achievments Corporate Governance Shareholder structure Social Policy Products    Over The Counter (OTC)    Prescription Pharmaceuticals (RX)    Vital and Essential Pharmaceuticals (VEP)    Third Parties Pharmaceuticals (TPP)    Research & Development Facilities Corporate film Reorganization Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
Corporate film
Markets information WAP version
Delayed according to exchanges regulations. RUSTOCKS.com
Company profile Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
© 2007–2013 All rights reserved.
Terms of use www.pharmstd.com